skip to content
Primary navigation


Drug - Juxtapid [Aegerion Pharmaceuticals, Inc.]

June 2013

Therapeutic area - Cardiovascular

Approval criteria

  • Patient is greater than 18 years of age AND
  • Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
  • Baseline liver function tests have been completed AND
  • Patient has tried and failed or is not a candidate for LDL-apheresis AND
  • Female patients have had a pregnancy test and a confirmed negative result

Quantity limit

  • 5 mg = 34
  • 10 mg = 34
  • 20 mg = 102

Background information

JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top